Přístupnostní navigace
E-application
Search Search Close
Project detail
Duration: 01.03.2022 — 28.02.2023
Funding resources
Brno University of Technology - Vnitřní projekty VUT
- whole funder (2022-01-01 - 2023-12-31)
On the project
Gene therapy using CRISPR/Cas9 is not accessible and equitable. That is due to complicated and costly ex vivo therapeutical process caused by the lack of versatile delivery platform able to be used systemically in vivo. In this project I will develop liposome-based delivery platform consisting of several types of lipids and pH sensitive structure enabling controlled release of CRISPR/Cas9 into cytoplasm. This liposome will be tested for gene knock-out. The proposed platform can be easily functionalized for cell-specific delivery or theranostics
Mark
CEITEC VUT-J-22-8056
Default language
Czech
People responsible
Heger Zbyněk, doc. - fellow researcherRessnerová Alžběta, M.Sc., MSc - principal person responsible
Units
Central European Institute of Technology BUT- (2022-01-01 - 2022-12-31)Smart Nanodevices- (2022-01-01 - 2022-12-31)